Lenalidomide Maintenance Therapy in Patients with Multiple Myeloma

被引：0
|
作者：
Fillitz, M. [1 ]
Seebacher, A. [1 ]
Reisner, R. [1 ]
Pittermann-Hocker, E. [1 ]
机构：
[1] Hanusch Hosp, Viennese Compulsory Hlth Insurance Fund WGKK, Vienna, Austria
来源：
CLINICAL LYMPHOMA & MYELOMA | 2009年 / 9卷
关键词：
D O I：
10.1016/S1557-9190(11)70632-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S90 / S90
页数：1
相关论文
共 50 条
  • [21] The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes
    Kesireddy, Meghana
    Holstein, Sarah A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (01) : 19 - 31
  • [22] MCT1 is a predictive marker for Lenalidomide maintenance therapy in multiple myeloma
    Stroh, J.
    Seckinger, A.
    Heider, M.
    Rudelius, M.
    Eichner, R.
    Schick, M.
    Slawska, J.
    Emde-Rajaratnam, M.
    Salwender, H.
    Bertsch, U.
    Goldschmidt, H.
    Weisel, K.
    Scheid, C.
    Keller, U.
    Hose, D.
    Bassermann, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 20 - 20
  • [23] MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
    Stroh, Jacob
    Seckinger, Anja
    Heider, Michael
    Rudelius, Martina
    Eichner, Ruth
    Schick, Markus
    Slawska, Jolanta
    Emde-Rajaratnam, Martina
    Salwender, Hans
    Bertsch, Uta
    Goldschmidt, Hartmut
    Weisel, Katja
    Scheid, Christof
    Keller, Ulrich
    Hose, Dirk
    Bassermann, Florian
    BLOOD ADVANCES, 2022, 6 (02) : 515 - 520
  • [24] Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT
    Syed, Yahiya Y.
    DRUGS, 2017, 77 (13) : 1473 - 1480
  • [25] Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-analysis Of Randomized Trials
    Singh, Preet Paul
    Kumar, Shaji K.
    LaPlant, Betsy R.
    Gertz, Morie A.
    Dispenzieri, Angela
    Bergsagel, P. Leif
    Lacy, Martha Q.
    Singh, Siddharth
    Roy, Vivek
    Buadi, Francis K.
    Dingli, David
    Kyle, Robert
    Rajkumar, S. Vincent
    Kapoor, Prashant
    BLOOD, 2013, 122 (21)
  • [26] Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT
    Yahiya Y. Syed
    Drugs, 2017, 77 : 1473 - 1480
  • [27] Deep Immune Profiling in Multiple Myeloma at Diagnosis and Under Lenalidomide Maintenance Therapy
    Silvennoinen, Raija Helena
    Javarappa, Komal Kumar
    Luoma, Sini
    Sergeev, Philipp
    Ohman, Tiina J.
    Varjosalo, Markku
    Anttila, Pekka
    Saily, Marjaana
    Partanen, Anu
    Sankelo, Marja
    Heckman, Caroline A.
    BLOOD, 2021, 138
  • [28] Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy
    Luoma, Sini
    Sergeev, Philipp
    Javarappa, Komal Kumar
    Ohman, Tiina J.
    Varjosalo, Markku
    Saily, Marjaana
    Anttila, Pekka
    Sankelo, Marja
    Partanen, Anu
    Nihtinen, Anne
    Heckman, Caroline A. A.
    Silvennoinen, Raija
    CANCERS, 2023, 15 (09)
  • [29] A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma
    Shin-ichi Fuchida
    Kazutaka Sunami
    Morio Matsumoto
    Hirokazu Okumura
    Tohru Murayama
    Toshihiro Miyamoto
    Eichi Otsuka
    Naohito Fujishima
    Tohru Izumi
    Shigehisa Tamaki
    Yasushi Hiramatsu
    Yoshiaki Kuroda
    Chihiro Shimazaki
    Koichi Akashi
    Mine Harada
    International Journal of Hematology, 2019, 109 : 107 - 114
  • [30] A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma
    Fuchida, Shin-ichi
    Sunami, Kazutaka
    Matsumoto, Morio
    Okumura, Hirokazu
    Murayama, Tohru
    Miyamoto, Toshihiro
    Otsuka, Eichi
    Fujishima, Naohito
    Izumi, Tohru
    Tamaki, Shigehisa
    Hiramatsu, Yasushi
    Kuroda, Yoshiaki
    Shimazaki, Chihiro
    Akashi, Koichi
    Harada, Mine
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (01) : 107 - 114
12345